Company’s 36-month beta value is 2.31.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 4 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ALRN is 13.81M, and currently, short sellers hold a 0.31% ratio of that floaft. The average trading volume of ALRN on May 02, 2024 was 72.12K shares.
ALRN) stock’s latest price update
The stock price of Aileron Therapeutics Inc (NASDAQ: ALRN) has dropped by -8.57 compared to previous close of 4.55. Despite this, the company has seen a fall of -15.62% in its stock price over the last five trading days. Zacks Investment Research reported 2023-04-04 that After losing some value lately, a hammer chart pattern has been formed for Aileron Therapeutics, Inc. (ALRN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
ALRN’s Market Performance
ALRN’s stock has fallen by -15.62% in the past week, with a monthly drop of -31.13% and a quarterly drop of -5.88%. The volatility ratio for the week is 10.86% while the volatility levels for the last 30 days are 13.50% for Aileron Therapeutics Inc The simple moving average for the past 20 days is -21.75% for ALRN’s stock, with a 33.72% simple moving average for the past 200 days.
Analysts’ Opinion of ALRN
Jefferies, on the other hand, stated in their research note that they expect to see ALRN reach a price target of $20. The rating they have provided for ALRN stocks is “Buy” according to the report published on July 24th, 2017.
BofA/Merrill gave a rating of “Buy” to ALRN, setting the target price at $19 in the report published on July 24th of the previous year.
ALRN Trading at -22.82% from the 50-Day Moving Average
After a stumble in the market that brought ALRN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -43.94% of loss for the given period.
Volatility was left at 13.50%, however, over the last 30 days, the volatility rate increased by 10.86%, as shares sank -28.77% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -11.86% lower at present.
During the last 5 trading sessions, ALRN fell by -15.62%, which changed the moving average for the period of 200-days by +112.24% in comparison to the 20-day moving average, which settled at $5.23. In addition, Aileron Therapeutics Inc saw 36.46% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ALRN starting from UNIVERSITY OF TEXAS/TEXAS AM I, who sale 20,315 shares at the price of $4.21 back on May 01 ’24. After this action, UNIVERSITY OF TEXAS/TEXAS AM I now owns 1,779,306 shares of Aileron Therapeutics Inc, valued at $85,473 using the latest closing price.
UNIVERSITY OF TEXAS/TEXAS AM I, the 10% Owner of Aileron Therapeutics Inc, sale 90 shares at $4.97 during a trade that took place back on Apr 30 ’24, which means that UNIVERSITY OF TEXAS/TEXAS AM I is holding 1,799,621 shares at $448 based on the most recent closing price.
Stock Fundamentals for ALRN
Current profitability levels for the company are sitting at:
- -121.55 for the present operating margin
- 0.11 for the gross margin
The net margin for Aileron Therapeutics Inc stands at -115.67. The total capital return value is set at -0.14. Equity return is now at value -123.34, with -22.27 for asset returns.
Based on Aileron Therapeutics Inc (ALRN), the company’s capital structure generated 0.93 points at debt to capital in total, while cash flow to debt ratio is standing at -0.22.
Currently, EBITDA for the company is -15.23 million with net debt to EBITDA at -5.19. When we switch over and look at the enterprise to sales, we see a ratio of 1080.04. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.17.
Conclusion
In a nutshell, Aileron Therapeutics Inc (ALRN) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
